HNN3.0
Register
Register
Register

Project cooperationUpdated on 7 December 2025

We seek cooperation in R&D, preclinical validation and regulatory studies to co-develop innovative solutions for the treatment of infected chronic wounds.

CEO at M2D1 Biossegurança

Santo André, Brazil

About

M2D1 is a Brazilian deep-tech company focused on developing advanced technologies for the management of infected chronic wounds. Our health project, BST22, is currently in preclinical validation and was designed to reduce microbial load, address biofilms and improve clinical outcomes through a safe, non-invasive approach.

We integrate biomedical engineering, applied microbiology, embedded intelligence and regulatory requirements to create an innovative medical device that supports healthcare professionals in treating complex wounds, including diabetic, pressure and vascular ulcers.

We seek international partners for cooperation in R&D, preclinical validation, regulatory studies and the design of future clinical trials. We are also interested in Horizon Europe consortia involving emerging medical technologies, infection management, healthy ageing and integrated care solutions.

M2D1 brings technical expertise, scientific rigor and active participation in innovation ecosystems, offering qualified contributions to high-impact collaborative health projects.

Organisation

M2D1 Biossegurança

Company (SME)

São Caetano do Sul, Brazil

Similar opportunities

  • Project cooperation

    Cell Therapy for Vascular Wounds - Gut Microbiota Modulation as a Therapeutic

    • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-15: Scaling up innovation in cardiovascular health
    • DESTINATION 1: HORIZON-HLTH-2026-01-STAYHLTH-03: Building public trust and outreach in the life sciences
    • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-03: Advancing research on the prevention, diagnosis, and management of post-infection long-term conditions
    • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-07: Establishing a European network of Centres of Excellence (CoEs) for Advanced Therapies Medicinal Products (ATMPs)
    • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-02: Innovative interventions to prevent the harmful effects of using digital technologies on the mental health of children and young adults

    Stefano De Monte

    Cluster Manager - Life Science Cluster Friuli Venezia Giulia at Life Science Cluster Friuli Venezia Giulia

    Trieste, Italy

  • Project cooperation

    DarkSeal: Dressing that heals

    • Partner seeks Consortium/Coordinator
    • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-09: Multisectoral approach to tackle chronic non-communicable diseases: implementation research maximising collaboration and coordination with sectors and in settings beyond the healthcare system (GACD)

    Jan Vícha

    Senior researcher at Tomas Bata University in Zlín

    Zlin, Czech Republic

  • Project cooperation

    Innovative phage-based antimicrobial therapies to tackle AMR in Horizon Europe projects

    • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-03: Advancing research on the prevention, diagnosis, and management of post-infection long-term conditions
    • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-07: Establishing a European network of Centres of Excellence (CoEs) for Advanced Therapies Medicinal Products (ATMPs)
    • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-06: Support to European Research Area (ERA) action on accelerating New Approach Methodologies (NAMs) to advance biomedical research and testing of medicinal products and medical devices

    Silvia Angeletti

    Full Professor Clinical Pathology and Head of Laboratory Unit at Fondazione Policlinico Universitario Campus Bio-Medico

    Rome, Italy